

## References

### Peer-reviewed articles

1. Rungger-Brändle E, **Liechti-Gallati S**, Gabbiani G, Moser H, Herschkowitz NN. Distribution of cytoskeletal elements in cultured skin fibroblasts of patients with Duchenne's muscular dystrophy. *Experientia* 1980; 36: 1204-1205.
2. **Liechti-Gallati S**, Moser H, Siegrist HP, Wiesmann U, Herschkowitz NN. Abnormal growth kinetics and 5'-nucleotidase activities in cultured skin fibroblasts from patients with Duchenne muscular dystrophy. *Pediatr Res* 1981; 15: 1411-1414.
3. **Liechti-Gallati S**, Braga S, Hirsiger H, Moser H. How many families will be informative for prenatal prediction of cystic fibrosis with multiple linked DNA probes ? *The Lancet II* 1986; 392-393.
4. **Liechti-Gallati S**, Braga S, Hirsiger H, Moser H. Familial deletion in Becker type muscular dystrophy within the pXJ region. *Hum Genet* 1987; 77: 267-268.
5. Moser H, **Liechti-Gallati S**, Braga S, Hirsiger H. Konduktorinnen-Diagnostik und praenatale Voraussagen mittels DNA-Analysen bei den X-chromosomalen Muskeldystrophien Duchenne und Becker. *Schw Med Wschr* 1987; 117:2061-2073.
6. Monaco AP, Bertelson CJ, **Liechti-Gallati S**, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics* 1988; 2: 90-95.
7. **Liechti-Gallati S**, Koenig M, Kunkel LM, Frey D, Boltshauser E, Schneider V, Braga S, Moser H. Molecular deletion patterns in Duchenne and Becker type muscular dystrophy. *Hum Genet* 1989; 81: 343-348.
8. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Müller CR, Lindlöf M, Kaariainen H, de la Chapelle A, Kiuru A, Savontaus M-L, Gilgenkrantz H, Recan D, Chelly J, Kaplan J-C, Covone AE, Archidiacono N, Romeo G, **Liechti-Gallati S**, Moser H, Schneider V, Braga S, Darras BT, Murphy P, Francke U, Chen JD, Morgan G, Denton M, Greenberg CR, Wrogemann K, Blonden LAJ, Paassen HMB, van Ommen GJB, Kunkel LM. The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. *Am J Hum Genet* 1989;45: 498-506.
9. **Liechti-Gallati S**, Niederer BU, Schneider V, Mächler M, Alkan M, Malik N, Braga S, Moser H. Haplotype analysis for CF-linked DNA-polymorphisms in Switzerland. *Clin Genet* 1990; 37: 442-449.
10. **Liechti-Gallati S**, Schneider V, Mullis P, Moser H. Restriction fragment length polymorphisms for Duchenne muscular dystrophy cDNA clones 9 and 10. *Am J Hum Genet* 1990; 46: 1090-1094.
11. **Liechti-Gallati S**, Dionisi Vici C, Bachmann C, Mazziotta MRM, Bartuli A, Sabetta G. Prenatal exclusion of ornithine transcarbamylase (OTC) deficiency by using RFLP analysis. *J Inher Met Dis* 1990; 13: 888-890.
12. Braga S, Gerber A, Meier C, Weiersmüller A, Zimmermann A, Herrmann U, **Liechti-Gallati S**, Moser H. Severe neonatal asphyxia due to X-linked centronuclear myopathy. *Eur J Pediatr* 1990; 150: 132-135.
13. Sennhauser F, **Liechti-Gallati S**, Moser H. Cystic fibrosis: carrier screening for partners of heterozygotes. *Brit Med J* 1990;301: 1081.
14. Thomas NST, Williams H, Cole G, Roberts K, Clarke A, **Liechti-Gallati S**, Braga S, Gerber A, Meier C, Moser H, Harper PS. X-linked neonatal centronuclear myotubular myopathy: evidence for linkage to Xq28 DNA marker loci. *J Med Genet* 1990; 27: 284-287.
15. **Liechti-Gallati S**, Parsai I, Kraemer R, Ruedeberg A, Braga S, Moser H. The delta F508-deletion in 99 CF patients of Switzerland. *Adv Exp Med Biol* 1991; 290: 367-368.

16. **Liechti-Gallati S**, Malik N, Alkan M, Maechler M, Morris M, Thonney F, Sennhauser F, Moser H. Association between DNA polymorphism haplotypes and specific mutations in the cystic fibrosis transmembrane conductance regulator gene. *Pediatr Res* 1991; 30: 304-308.
17. **Liechti-Gallati S**, Dionisi Vici C, Bachmann C, Wermuth B, Colombo JP. Direct and indirect mutation analyses in patients with OTC deficiency. *Enzyme* 1991; 45: 81-91.
18. Blondin LAJ, Grootsholten PM, den Dunnen JT, Bakker E, Abbs S, Bobrow M, Boehm C, van Broeckhoven C, Baumbach L, Chamberlain J, Caskey C, Denton M, Felicetti L, Fishbeck K, Francke U, Gilgenkrantz H, Kaplan J-C, Herrmann F, Junien C, Boileau C, Liechti- **Gallati S**, Lindlöf M, Matsumoto T, Müller C, Poncin J, Malcolm S, Robertson E, Romeo G, Covone A, Scheffer H, Schröder E, Schwartz M, Verellen C, Walker A, Worton R, Gillard E, van Ommen GBJ. 242 breakpoints in the 200-kb deletion-prone P20 region of the DMD gene are widely spread. *Genomics* 1991;10: 631-639.
19. **Liechti-Gallati S**, Müller B, Grimm T, Kress W, Müller C, Boltshauser E, Moser H, Braga S. X-linked centronuclear myopathy: mapping the gene to Xq28. *Neuromusc Disord* 1992; 1: 239-245.
20. **Liechti-Gallati S**, Bonsall I, Malik N, Schneider V, Kraemer LG, Moser H, Ruedeberg A, Kraemer R. Genotype/phenotype association in cystic fibrosis (CF): analyses of the  $\Delta F508$ , R553X, and 3905insT mutations. *Pediatr Res* 1992; 32: 175-178.
21. Van Essen AJ, Abbs S, Baiget M, Bakker E, Boileau C, van Broeckhoven C, Bushby K, Clarke A, Claustres M, Covone AE, Ferrari M, Ferlini A, Galluzzi G, Grimm T, Grubben C, Jeanpierre M, Kääriäinen H, **Liechti-Gallati S**, Melis MA, van Ommen GJB, Poncin JE, Scheffer H, Schwartz M, Speer A, Stuhmann M, Verellen-Dumoulin C, Wilcox DE, ten Kate LP. Parental origin and germline mosaicism of deletions and duplications of the dystrophin gene: a European study. *Hum Genet* 1992; 88: 249-257.
22. Mullis PE, **Liechti-Gallati S**, Di Silvio L, Brook CGD, Paes-Alves AF. Short stature in a patient with cystic fibrosis caused by a 6.7 kb human growth hormone gene (hGH-1) deletion. *Hormone Res* 1992; 36: 4-8.
23. Grimm T, **Liechti-Gallati S**, Voit T, Kress W, Kullmann F, Steinbach P, Müller CR. Duchennesche Muskeldystrophie: X-chromosomaler und autosomal rezessiver Erbgang. *Aktuelle Myologie, Pongratz D., Reimers C.D., Urban & Schwarzenberg* (1992)
24. Müller B, Platz U, **Liechti-Gallati S**, Moser H, Müller CR, Kress W, Bettecken T, Meng G, Kullmann F, Grimm T. Populationsgenetik der Duchenneschen Muskeldystrophie: männliche und weibliche Mutationsrate sowie Ursprung der Mutation. *Aktuelle Myologie, Pongratz D., Reimers C.D., Urban & Schwarzenberg* (1992)
25. Müller B, Dechant C, Meng G, **Liechti-Gallati S**, Doherty RH, Hejtmancik JF, Bakker E, Read AP, Jeanpierre M, Fischbeck KH, Romeo G, Francke U, Willichowski E, Greenberg CR, van Broeckhoven C, Boileau C, Müller CR, Grimm T. Estimation of the male and female mutation rates in Duchenne muscular dystrophy. *Hum Genet* 1992; 89: 204-206.
26. Fey MF, Peter H-J, Hinds HL, Zimmermann A, Gerber H, **Liechti-Gallati S**, Studer H, Tobler A. Clonal analysis of human tumours with M27B, a highly informative polymorphic X-chromosomal probe. *J Clin Invest* 1992; 89: 1438-1444.
27. Sander AK, **Liechti-Gallati S**, Kunze N, Moser H, Zingg M, Raveh J. An EcoRI polymorphism for the glutamyl-tRNA synthetase (QUARS) gene on chromosome 1q. *Hum Mol Genet* 1992; 1: 288.
28. Sander AK, Moser H, **Liechti-Gallati S**, Grimm T, Zingg M, Raveh J. Linkage of Van der Woude syndrome (VWS) to REN and exclusion of the candidate gene TGFB2 from the disease locus in a large pedigree. *Hum Genet* 1993; 91: 55-62.
29. **Liechti-Gallati S**, Wolff G, Ketelsen U-P, Braga S. Prenatal diagnosis of X-linked centronuclear myopathy. *Pediatr Res* 1993; 33: 201-204.
30. Von Mitzlaff H-C, **Liechti-Gallati S**, Rösler KM, Burgunder J-M. Die Quadrizepsmyopathie als Dystrophin-assoziierte Myopathie. *Schweiz Med Wochenschr* 1993; 123: 1865-1869.

31. Fey M, **Liechti-Gallati S**, von Rohr A, Borisch B, Theilkäs L, Schneider V, Oestreicher M, Nagel S, Ziemięcki A, Tobler A: Clonality and X-inactivation patterns in haematopoietic cell populations detected by the highly informative M27beta DNA probe. *Blood* 1994; 83: 931-938.
32. **Liechti-Gallati S**, Borer U. Vorproben mit Hemastix- und Sangur-Teststäbchen sowie Phosphatesmo KM-Testpapier beeinflussen die DNA-Typisierung von Blut- und Spermaspuren nicht. *Archiv für Kriminologie* 1994; 193: 37-42.
33. Sander A, Moser H, Grimm T, **Liechti-Gallati S**, Malipiero U, Raveh J. Gen-Lokalisation des Van-der-Woude-Syndroms. *Dtsch Z Mund Kiefer GesichtsChir* 1994; 18: 184-189.
34. Birrer P, McElvaney NG, Rudeberg A, Wirz Sommer C, **Liechti-Gallati S**, Kraemer R, Hubbard R, Crystal RG. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. *Am J Respir Crit Care Med* 1994; 150: 207-213.
35. Grimm T, Meng G, **Liechti-Gallati S**, Bettecken T, Müller CR, Müller B. On the origin of deletions and point mutations in Duchenne muscular dystrophy: most deletions arise in oogenesis and most point mutations result from events in spermatogenesis. *J Med Genet* 1994; 31: 183-186.
36. Oppliger Leibundgut E, **Liechti-Gallati S**, Colombo J-P, Wermuth B. Ornithine transcarbamylase deficiency: New sites with increased probability of mutation. *Hum Genet* 1995; 95: 191-196.
37. Neeser D, **Liechti-Gallati S**. Sex determination of forensic samples by simultaneous PCR amplification of alpha-satellite DNA from both the X and Y chromosomes. *J Forensic Sciences* 1995; 40: 239-241.
38. **Liechti-Gallati S**, Kraemer R. Cystic fibrosis mutations and immotile cilia syndrome. *Clin Genet* 1995; 47: 328-329.
39. Pedrolis G, **Liechti-Gallati S**, Mauri S, Birrer P, Kraemer R, Foletti-Jäggi C, Bianchetti MG. Chronic metabolic alkalosis: not uncommon in young children with severe cystic fibrosis. *Am J Nephrol* 1995; 15: 245-250.
40. Aebi C, Bracher R, **Liechti-Gallati S**, Tschäppeler H, Rudeberg A, Kraemer R. The age at onset of chronic *Pseudomonas aeruginosa* colonization in cystic fibrosis - prognostic significance. *Eur J Pediatr* 1995; 154: Suppl 4, S69-S73.
41. Cuppens H, Cassiman J-J, The European Concerted Action on Cystic Fibrosis. A quality control study of CFTR mutation screening in 40 different European laboratories. *Eur J Hum Genet* 1995; 3: 235-245.
42. Ten Kate LP, Chevalier F, Bozon D, Estivill X, Casals T, Abeliovich D, Lerer I, Padoan R, Seia M, Hill A, **Liechti-Gallati S**, Kraemer R, Beards F, Dear S, Dallapiccola B, Sangiuolo F, Macek M Jr, Macek M, McMahonR, Connarty M, Harvey JF, Claustres M, Desgeorges M, de Vries R, Scheffer H, Canki-Klain N, Audrezet MP, Bienvenu T, Chomel JC, Dziadek V, Tümmler B, Schwarz M, Haworth A, Benitez J, Fernandez E, Mazurczak T, Bal J, Cremonesi L, Cashman SM, Ferec C, Cuppens H, Bauer I, Angelicheva D, Wagner K, Pacheco P, Bonizzato A, Witt M, McMahon CJ, Ravnik-Glavac M, Reis A, Stuhmann M, Garnerone S, Curtis A, Grüning G, Kanavakis E, Klaassen T, Grade K. No evidence for segregation distortion of CF alleles among sibs of CF patients. *Eur J Hum Genet* 1995; 3: 324-325.
43. Sonntag J, Gaude M, **Liechti-Gallati S**, Göbel HH, Smolenicka Z, Muhle H, Weisner D, Schaub J. X-chromosomale myotubuläre Myopathie - ein perinatologisches Problem. 3 Kasuistiken mit molekulargenetischen Befunden. *Perinatal Medizin* 1995; 7: 93-97.
44. Marti U, Elsing C, Renner EL, **Liechti-Gallati S**, Reichen J. Differential expression of Na<sup>+</sup>, H<sup>+</sup> - antiporter mRNA in biliary epithelial cells and in hepatocytes. *J Hepatol* 1996; 24: 498-502.
45. Oppliger Leibundgut E, Colombo J-P, Wermuth B, **Liechti-Gallati S**. Identification of four novel splice site mutations in the ornithine transcarbamylase gene. *Hum Genet* 1996; 97: 209-213.
46. **Liechti-Gallati S**, Neeser D. Efficient and reliable PCR-based detection of the ABO blood group alleles: Genotyping on stamps and other biological evidence samples. *J Forensic Sciences* 1996; 41: 653-657.

47. Kioschis P, Rogner UC, Pick E, Klauck SM, Heiss N, Siebenhaar R, Korn B, Coy JF, Laporte J, **Liechti-Gallati S**, Poustka A. A 900-kb cosmid contig and 10 new transcripts within the candidate region for myotubular myopathy (MTM1). *Genomics* 1996; 33: 365-373.
48. Oppliger Leibundgut E, Wermuth B, Colombo J-P, **Liechti-Gallati S**. Ornithine transcarbamylase deficiency: Characterization of gene mutations and polymorphisms. *Hum Mutat* 1996; 8: 333-339.
49. Smolenicka Z, Laporte J, Hu L, Dahl N, Fitzpatrick J, Kress W, **Liechti-Gallati S**. X-linked myotubular myopathy (MTM1): refinement of the critical gene region. *Neuromusc Disord* 1996; 6: 275-281.
50. Smolenicka Z, Guerini D, Carafoli E, Kress W, **Liechti-Gallati S**. Detection of a new polymorphism in the plasma membrane Ca<sup>2+</sup> ATPase isoform 3 gene and its exclusion as a candidate for X-linked myotubular myopathy (MTM1). *Hum Genet* 1996; 98: 681-684.
51. Ruesch S, Krähenbühl S, Kleinle S, **Liechti-Gallati S**, Schaffner T, Wermuth B, Weber J, Wiesmann UN. Combined 3-methylglutaconic and 3-hydroxy-3-methyl-glutaric aciduria with endocardial fibroelastosis and dilative cardiomyopathy in male and female siblings with partial deficiency of complex II/III in fibroblasts. *Enzyme Protein* 1996; 49: 321-329.
52. Oppliger Leibundgut E, **Liechti-Gallati S**, Colombo J-P, Wermuth B. Ornithine transcarbamylase deficiency: Ten new mutations and high proportion of de novo mutations in heterozygous females. *Hum Mutat* 1997; 9: 409-411.
53. Laporte J, Guiraud-Chaumeil C, Vincent M-C, Mandel J-M, Tanner SM, **Liechti-Gallati S**, Wallgren-Pettersson C, Dahl N, Kress W, Bolhuis PA, Fardeau M, Samson F, Bertini E. Mutations in the MTM1 gene implicated in X-linked myotubular myopathy. *Hum Mol Genet* 1997; 6: 1505-1511.
54. Stadge SI, Wiesmann U, Superti-Furga A, Krähenbühl S, Boltshauser E, Reichen J, **Liechti-Gallati S**. Detection and characterization of mitochondrial DNA rearrangements in Pearson and Kearns-Sayre syndromes by long PCR. *Hum Genet* 1997; 100: 643-650.
55. Estivill X. and the Biomed CF Mutation Analysis Consortium. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. *Hum Mutat* 1997; 10: 135-154.
56. Hergersberg M, Balakrishnan J, Bettecken T, Chevalier-Porst F, Brägger C, Burger R, Einschenk I, **Liechti-Gallati S**, Morris M, Schorderet D, Thonney F, Moser H, Malik N. A new mutation, 3905insT, accounts for 4.8% of 1173 CF chromosomes in Switzerland and causes a severe phenotype. *Hum Genet* 1997; 100: 220-223.
57. Tanner SM, Laporte J, Guiraud-Chaumeil C, **Liechti-Gallati S**. Confirmation of prenatal diagnosis results of X-linked recessive myotubular myopathy by mutational screening, and description of three new mutations in the MTM1 gene. *Hum Mutat* 1998; 11: 62-68.
58. Smolenicka Z, Bach E, Schaer A, **Liechti-Gallati S**, Frey BM, Frey FJ, Ferrari P. A new polymorphic restriction site in the human 11 $\beta$ -hydroxysteroid dehydrogenase type 2 gene. *J Clin Endocr Metab* 1998; 83: 1814-1817.
59. Laporte J, Guiraud-Chaumeil C, Tanner SM, Blondeau F, Hu L-J, Vicaire S, **Liechti-Gallati S**, Mandel J-M. Genomic organization of the MTM1 gene implicated in X-linked myotubular myopathy. *Eur J Hum Genet* 1998; 6: 325-330.
60. Kleinle S, Schneider V, Moosmann P, Brander S, Krähenbühl S, **Liechti-Gallati S**. A novel mitochondrial tRNAPhe mutation inhibiting anticodon stem formation associated with a muscle disease. *Biochem Biophys Res Comm* 1998; 247:112-115.
61. Jaksch M, Hofmann S, Kleinle S, **Liechti-Gallati S**, Pongratz DE, Müller-Höcker J, Baldwin Jedede K, Meitinger T, Gerbitz K-D. A systematic mutation screen of 10 nuclear and 25 mitochondrial candidate genes in 21 patients with cytochrome c oxidase (COX) deficiency reveals tRNASer(UCN) mutations in a subgroup with syndromal encephalopathy. *J Med Genet* 1998; 35: 895-900.

62. Kraemer R, Birrer P, **Liechti-Gallati S**. Genotype-phenotype association in infants with cystic fibrosis at the time of diagnosis.  
*Pediatr Res* 1998 44: 920-926.
63. Rohrbach M, Kraemer R, **Liechti-Gallati S**. Screening of the FceRI $\beta$ -gene in a Swiss population of asthmatic children: no association with E237G and identification of new sequence variations.  
*Disease Markers* 1998; 14: 177-186.
64. Tanner SM, Schneider V, Thomas NST, Clarke A, Lazarou L, **Liechti-Gallati S**. Characterization of 34 novel and 6 known MTM1 gene mutations in 47 unrelated X-linked myotubular myopathy patients.  
*Neuromusc disord* 1999; 9: 41-49.
65. Moshfegh K, Wuillemin WA, Redondo M, Lämmle B, Beer JH, **Liechti-Gallati S**, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia / IIa receptor with risk of myocardial infarction: a case-control study.  
*The Lancet* 1999; 353: 351-354.
66. Tanner SM, Orstavik KH, Kristiansen M, Lev D, Lerman-Sagie T, Sadeh M, **Liechti-Gallati S**. Skewed X inactivation in a manifesting carrier of X-linked myotubular myopathy, and in her non-manifesting carrier mother.  
*Hum Genet* 1999; 104: 249-253.
67. **Liechti-Gallati S**, Schneider V, Neeser D, Kraemer R. Two buffer system-based SSCP/HD analysis: a general protocol for rapid and sensitive mutation screening in cystic fibrosis and any other human genetic disease.  
*Eur J Hum Genet* 1999; 7: 590-598.
68. Rohrbach M, Frey U, Kraemer R, **Liechti-Gallati S**. A variant in the gene for granulocyte macrophage-colony stimulating factor, I117T, is associated with atopic asthma in a Swiss population of asthmatic children.  
*J Allergy Clin Immunol* 1999; 104: 247-248.
69. Krähenbühl S, Kleinle S, Henz S, Leibundgut K, **Liechti-Gallati S**, Zimmermann A, Wiesmann U. Microvesicular steatosis, hemosiderosis and rapid development of liver cirrhosis in a patient with Pearson's syndrome.  
*J Hepatology* 1999; 31: 550-555.
70. Bennett L-C, Kraemer R, **Liechti-Gallati S**. Mutation screening of the complete cystic fibrosis transmembrane conductance regulator (CFTR) coding region in buccal epithelial cells from premature and term new-borns.  
*Eur J Pediatrics* 2000; 159: 99-102.
71. Laporte J, Biancalana V, Tanner SM, Kress W, Schneider V, Wallgren-Pettersson, Herger F, Buj-Bello A, Blondeau F, **Liechti-Gallati S**, Mandel J-L. MTM1 mutations in X-linked myotubular myopathy.  
*Hum Mutat* 2000; 15: 393-409.
72. Krähenbühl S, Brandner S, Kleinle S, **Liechti S**, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure.  
*Liver* 2000; 20: 346-348.
73. Kraemer R, Aebi C, Casaulta Aebischer C, **Gallati S**. Early detection of lung disease and its association with the nutritional status, genetic background and life events in patients with cystic fibrosis.  
*Respiration* 2000; 67: 477-490.
74. Sutton IJ, Winer JB, Norman AN, **Gallati S**, MacDonald F. Limb girdle and facial weakness in female carriers of X-linked myotubular myopathy mutations.  
*Neurology* 2001; 57: 900-902.
75. Liniger M, Bodenmüller K, Pays E, **Gallati S**, Roditi I. Overlapping sense and antisense transcription units in *Trypanosoma brucei*.  
*Molecular Microbiol* 2001; 40: 869-878.
76. Matovu E, Geiser F, Schneider V, Maser P, Enyaru JC, Kaminsky R, **Gallati S**, Seebeck T. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy.  
*Mol Biochem Parasitol* 2001; 117:73-81.
77. Vuissoz JM, Deladoey J, Buyukgebiz A, Cemeroglu P, Gex G, **Gallati S**, Mullis PE. New autosomal recessive mutation of the tsh-beta subunit gene causing central isolated hypothyroidism.  
*J Clin Endocrinol Metab* 2001; 86:4468-71.
78. Schibler A, Bolt I, **Gallati S**, Schoni MH, Kraemer R. High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and deltaF508.  
*Eur Respir J* 2001; 17:1181-1186.

79. Jaksch M, Kleinle S, Scharfe C, Klopstock T, Pongratz D, Muller-Hocker J, Gerbitz KD, **Gallati S**, Lochmuller H, Horvath R. Frequency of mitochondrial transfer RNA mutations and deletions in 225 patients presenting with respiratory chain deficiencies.  
*J Med Genet* 2001; 38: 665-673.
80. Buhr A, Bianchi MT, Baur R, Courtet P, Pignay V, Boulenger JP, **Gallati S**, Hinkle DJ, McDonald RL, Sigel E. Functional characterization of the new human GABA<sub>A</sub> receptor mutation b3 (R192H).  
*Hum Genet* 2002; 111: 154-160.
81. Lin S, Ramelli GP, Moser H, **Gallati S**, Burgunder JM. A novel insert in gamma-sarcoclycan gene leads to severe childhood autosomal recessive muscular dystrophy.  
*J Neurol* 2002; 249: 1608-1611.
82. Biancalana V, Caron O, **Gallati S**, Baas F, Kress W, Novelli G, Lagier-Tourenne C, Buj-Bello A, Romero N, Mandel JL. Characterisation of mutations in 77 patients with X-linked myotubular myopathy including a family with a very mild phenotype.  
*Hum Genet* 2003; 112: 135-142.
83. Chen L, Lang D, Ran XW, Joncourt F, **Gallati S**, Burgunder JM. Clinical and molecular analysis of Chinese patients with thyrotoxic periodic paralysis.  
*Eur Neurol* 2003; 49: 227-230.
84. Besson A, Salemi S, **Gallati S**, Jenal A, Horn R, Mullis PS, Mullis PE. Reduced longevity in untreated patients with isolated growth hormone deficiency.  
*J Clin Endocrinol Metab* 2003; 88: 3664-3667.
85. Salemi S, Besson A, Eblé A, **Gallati S**, Pfäffle RW, Mullis PE. New N-terminal located mutation (Q4ter) within the POU1F1-gene (PIT-1) causes recessive combined pituitary hormone deficiency and variable phenotype.  
*Growth Hormone & IGF Research* 2003; 13: 264-268.
86. Kristiansen M, Knudsen GP, Tanner SM, McEntagart M, Jungbluth H, Muntoni F, Sewry C, **Gallati S**, Orstavik KH, Wallgren-Pettersson C. X-inactivation patterns in carriers of X-linked myotubular myopathy.  
*Neuromuscul Disord* 2003; 13: 468-471.
87. Besson A, Salemi S, Eblé A, Joncourt F, **Gallati S**, Jorge AAL, Mullis PE. Primary GH insensitivity (Laron syndrome) caused by a novel 4kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I.  
*Eur J Endocrinol* 2004; 150: 635-642.
88. Chen L, Schaerer M, Lu ZH, Lang D, Joncourt F, Weis J, Fritschi J, Kappeler L, **Gallati S**, Siegel E, Burgunder JM. Exon 17 skipping in CLCN1 leads to recessive myotonia congenita.  
*Muscle Nerve* 2004; 29: 670-676.
89. Joncourt F, Neuhaus B, Jostardt-Foegen K, Kleinle S, Steiner B, **Gallati S**. Rapid identification of female carriers of DMD/BMD by quantitative real-time PCR.  
*Hum Mutat* 2004; 23: 385-391.
90. Steiner B, Truninger K, Sanz J, Schaller A, **Gallati S**. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles.  
*Hum Mutat* 2004; 24: 120-129.
91. Férec C, Le Maréchal C, Audrézet MP, Farinha CM, Amaral MD, **Gallati S**, Sanz J, Steiner B, Mouchel N, Harris A, Schwarz MJ. Analysis of genomic CFTR DNA.  
*J Cystic Fibrosis* 2004; 3(S2):7-10.
92. Ramalho AS, Beck S, Farinha CM, Clarke LA, Heda GD, Steiner B, Sanz J, **Gallati S**, Amaral MD, Harris A, Tzetzis M. Methods for RNA extraction, cDNA preparation and analysis of CFTR transcripts.  
*J Cystic Fibrosis* 2004; 3(S2):11-15.
93. Amaral MD, Clarke LA, Ramalho AS, Beck S, Broackes-Carter F, Rowntree R, Mouchel N, Williams SH, Harris A, Tzetzis M, Steiner B, Sanz J, **Gallati S**, Nissim-Rafinifa M, Kerem B, Hefferon T, Cutting GR, Goina E, Pagani F. Quantitative methods for the analysis of CFTR transcripts/splicing variants.  
*J Cystic Fibrosis* 2004; 3(S2):17-23.
94. Kaiser FJ, Brega P, Raff ML, Byers PH, **Gallati S**, Taylor Kay T, de Almeida S, Horsthemke B, Lüdecke H-J. Novel missense mutations in the TRPS1 transcription factor define the nuclear localization signal.  
*Eur J Hum Genet* 2004; 12: 121-126.
95. Kraemer R, Blum A, Schibler A, Ammann R, **Gallati S**. Ventilation Inhomogeneities in Relation to Standard Lung Function in Patients with Cystic Fibrosis.  
*Am J Respir Crit Care Med* 2005; 171:371-378.

96. Pavlovic M, Schaller A, Pfammatter JP, Carrel T, Berdat P, **Gallati S**. Age-dependent suppression of SERCA2a mRNA in pediatric atrial myocardium. *Biochem Biophys Res Commun* 2005; 326: 344-348.
97. Derichs N, Schuster A, Grund I, Ernsting A, Stolpe C, Kortge-Jung S, **Gallati S**, Stuhmann M, Kozlowski P, Ballmann M. Homozygosity for L997F in a child with normal clinical and chloride secretory phenotype provides evidence that this cystic fibrosis transmembrane conductance regulator mutation does not cause cystic fibrosis. *Clin Genet* 2005; 67: 529-531.
98. Pavlovic M, Schaller A, Ammann RA, Sanz J, Pfammatter JP, Carrel T, Berdat P, **Gallati S**. Cardiopulmonary bypass reduces atrial Na<sup>+</sup>-K<sup>+</sup>-ATPase expression in children. *Biochem Biophys Res Commun* 2005; 335: 700-704.
99. Maciel P, Cruz VT, Constante M, Iniesta I, Costa MC, **Gallati S**, Sousa N, Sequeiros J, Coutinho P, Santos MM. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. *Neurology* 2005; 65: 603-605.
100. Rittinger O, Sander G, Schaller A, **Gallati S**, Mayr H, Sperl W. Menkes' disease: heterozygosity testing by quantitative real-time PCR and the dilemma of therapeutic support. *Klin Padiatr* 2005; 217: 286-290.
101. Pavlovic M, Schaller A, Steiner B, Berdat P, Carrel T, Pfammatter JP, **Gallati S**. Gender modulates the expression of calcium-regulating proteins in pediatric atrial myocardium. *Exp Biol Med* 2005; 230: 853-859.
102. Pavlovic M, Schaller A, Ammann RA, Sanz J, Pfammatter JP, Carrel T, Berdat P, **Gallati S**. Reduced atrial connexin43 expression after pediatric heart surgery. *Biochem Biophys Res Commun* 2006; 342: 310-315.
103. Schaller A, Troller R, Molina D, **Gallati S**, Aepli C, Stutzmann Meier P. Rapid typing of *Moraxella catarrhalis* subpopulations based on outer membrane proteins using mass spectrometry. *Proteomics* 2006; 6: 172-180.
104. Olivares JL, Bueno I, **Gallati S**, Ramos FJ. Late-onset treatment in Menkes disease: is there a correlation between genotype and response to therapy? *Clin Genet* 2006; 69: 363-366.
105. Pavlovic M, Schaller A, Ammann RA, Pfammatter JP, Berdat P, Carrel T, **Gallati S**. Sodium pump reduction correlates with aortic clamp time in pediatric heart surgery. *Exp Biol Med* 2006; 231: 1300-1305.
106. Ramelli GP, **Gallati S**, Weis J, Krähenbühl S, Burgunder JM. Point mutation tRNA(Ser(UCN)) in a child with hearing loss and myoclonus epilepsy. *J Child Neurol* 2006; 21: 253-255.
107. Kraemer R, Delosea N, Ballinari P, **Gallati S**, Cramer R. Effect of allergic broncho-pulmonary aspergillosis on lung function in children with Cystic Fibrosis. *Am J Respir Crit Care Med* 2006; 174: 1211-1220.
108. Kraemer R, Baldwin DN, Ammann RA, Frey U, **Gallati S**. Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. *Respir Res* 2006; 7: 138-152.
109. Schneider M, Joncourt F, Sanz J, von Känel T, **Gallati S**. Detection of exon deletions within an entire gene (CFTR) by relative quantification on the LightCycler. *Clin Chem* 2006; 52: 2005-2012.
110. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vtzthum H, Sasaki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Ariceta G, Cano F, Enriquez R, Juppner H, Bakaloglu SA, Hediger MA, **Gallati S**, Neuhauss SC, Nurnberg P, Weber S. Mutations in the tight-junction gene Claudin 19 (CLDN19) are associated with renal Magnesium wasting, renal failure, and severe ocular involvement. *Am J Hum Genet* 2006; 79: 949-957.
111. Schaller A, von Känel T, Gehr B, Sanz J, **Gallati S**. Rapid and reliable genotyping of polymorphic loci modifying correct splicing of CFTR pre-mRNA using mass spectrometry. *Eur J Hum Genet* 2007; 15: 53-61.
112. Schuepbach WM, Vadday KM, Schaller A, Breckenfeld C, Kappeler L, Benoist JF, Xuan-Huong CN, Burgunder JM, Seibold F, **Gallati S**, Mattle HP. Mitochondrial neurogastrointestinal encephalomyopathy in three siblings: Clinical genetic and neuroradiological features. *J Neurol* 2007; 254: 146-153.

113. Wiszniewski L, Sanz J, Scerri I, Gasparotto E, Dudez T, Lacroix JS, Suter S, **Gallati S**, Chanson M. Functional expression of connexin30 and connexin31 in the polarized human airway epithelium. *Differentiation* 2007; 75: 382-392.
114. Pachlopnik Schmid JM, Kuehni CE, Strippoli MP, Roiha HL, Pavlovic R, Latzin P, **Gallati S**, Kraemer R, Dahinden C, Frey U. Maternal tobacco smoking and decreased leukocytes, including dendritic cells, in neonates. *Pediatr Res* 2007; 61: 462-466.
115. Von Känel T, Adolf F, Schneider M, **Gallati S**. Sample number and denaturation time are crucial for the accuracy of capillary-based LightCyclers. *Clin Chem* 2007; 53: 1392-1394.
116. Schneider M, Hirt C, Casaulta C, Barben J, Spinaz R, Bühlmann U, Spalinger J, Schwizer B, Chevalier-Porst F, **Gallati S**. Large deletions in the CFTR gene: clinics and genetics in Swiss patients with CF. *Clin Genet* 2007; 72: 30-38.
117. Akhvlediani T, Sandor PS, Henning A, Schaller A, Jauslin M, **Gallati S**, Boesiger P, Jung HH. Mitochondrial encephalopathy with CADASIL-like MRI. *Eur Neurol* 2007; 58: 185-188.
118. Iliev ME, Bodmer S, **Gallati S**, Lanz R, Sturmer J, Katsoulis K, Wolf S, Trittbach P, Sarra GM. Glaucoma phenotype in a large Swiss pedigree with myocilin Gly367Arg mutation. *Eye* 2008; 22: 880-888.
119. Konrad M, Hou J, Weber S, Dötsch J, Kari JA, Seeman T, Kuwrtz-Bröking E, Peco-Antic A, Tasic V, Dittrich K, Alshaya HO, von Vigier RO, **Gallati S**, Goodenough DA, Schaller A. CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 2008; 19: 171-181.
120. Stanke F, Ballmann M, Bronsveld I, Dörk T, **Gallati S**, Laabs U, Derichs N, Ritzka M, Posselt HG, Harms HK, Griese M, Blau H, Mastella G, Bijman J, Veeze H, Tümmler B. Diversity of the basic defect of homozygous CFTR mutation genotypes in humans. *J Med Genet* 2008; 45: 47-54.
121. Mefford HC, Sharp AJ, Baker C, Itsara A, Jiang Z, Buysse K, Huang S, Maloney VK, Crolla JA, Baralle D, Collins A, Mercer C, Norga K, de Ravel T, Devriendt K, Bongers EM, de Leeuw N, Reardon W, Gimelli S, Bena F, Hennekam RC, Male A, Gaunt L, Clayton-Smith J, Simoncic I, Park SM, Mehta SG, Nik-Zainal S, Woods CG, Firth HV, Parkin G, Fichera M, Reitano S, Giudice ML, Li KE, Casuga I, Broome A, Conrad B, Schwerzmann M, Räber L, **Gallati S**, Striano P, Coppola A, Tolmie JL, Tobias ES, Lilley C, Armengol L, Spyschaert Y, Verloo P, De Coene A, Goossens L, Mortier G, Speleman F, van Binsbergen E, Nelen MR, Hochstenbach R, Poot M, Gallagher L, Gill M, McClellan J, King MC, Regan R, Skinner C, Stevenson RE, Antonarakis SE, Chen C, Estivill X, Menten B, Gimelli G, Gribble S, Schwartz S, Sutcliffe JS, Walsh T, Knight SJ, Sebat J, Romano C, Schwartz CE, Veltman JA, de Vries BB, Vermeesch JR, Barber JC, Willatt L, Tassabehji M, Eichler EE. Recurrent Rearrangements of Chromosome 1q21.1 and Variable Pediatric Phenotypes. *N Engl J Med* 2008; 359: 1685-1699.
122. Schneider M, von Känel T, Sanz J, **Gallati S**. Ligation dependent allele specific quantification (LASQ) of CFTR cDNA on the LightCycler using MLPA hybridization probes. *Clin Chim Acta* 2009; 402: 47-53.
123. Kraemer R, Latzin P, Pramana I, Ballinari P, **Gallati S**, Frey U. Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis. *Respir Res* 2009; 10:106-117.
124. **Gallati S**, Hess S, Galié-Wunder D, Berger-Menz E, Böhlen D. Cystic fibrosis transmembrane conductance regulator mutations in azoospermic and oligospermic men and their partners. *RBM Online* 2009; 19: 685-694.
125. Sanz J, von Känel T, Schneider M, Steiner B, Schaller A, **Gallati S**. The CFTR frameshift mutation 3905insT and its effect at transcript and protein level. *Eur J Hum Genet* 2010; 18: 212-217.
126. Von Känel T, Gerber D, Schaller A, Baumer A, Wey E, Jackson C, Gisler FM, Heinemann K, **Gallati S**. Quantitative one-step DNA methylation analysis using native genomic DNA as template. *Clin Chem* 2010; 56: 1098-1106.
127. Derichs N, Sanz J, von Känel T, Stolpe C, Zapf A, Tümmler B, **Gallati S**, Ballmann M. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. *Thorax* 2010; 65: 594-599.



128. Wingeier K, Giger E, Strozzi S, Kreis R, Joncourt F, Conrad B, **Gallati S**, Steinlin M. Neuropsychological impairments and the impact of dystrophin mutations on general cognitive functioning of patients with Duchenne muscular dystrophy. *J Clin Neurosci*. 2011; 18: 90-95.
129. Schaller A, Hahn D, Jackson CB, Kern I, Chardot C, Belli DC, **Gallati S**, Nuoffer JM. Molecular and biochemical characterisation of a novel mutation in POLG associated with Alpers syndrome. *BMC Neurol* 2011; 11: 4-10.
130. Schaller A, Desetty R, Hahn D, Jackson CB, Nuoffer JM, **Gallati S**, Levinger L. Impairment of mitochondrial tRNA(Ile) processing by a novel mutation associated with chronic progressive external ophthalmoplegia. *Mitochondrion* 2011 Feb 1: 1-9.
131. Hurst JA, Jenkins D, Vasudevan PC, Kirchhoff M, Skovby F, Rieubland C, **Gallati S**, Rittinger O, Kroisel PM, Johnson D, Biesecker LG, Wilkie AO. Metopic and sagittal synostosis in Greig cephalopolysyndactyly syndrome: five cases with intragenic mutations or complete deletions of GLI3. *Eur J Hum Genet* 2011; 19: 757-762.
132. Steiner B, Rosendahl J, Witt H, Teich N, Keim V, Schulz HU, Pfützer R, Lühr M, Gress TM, Nickel R, Landt O, Koudova M, Macek M Jr, Farre A, Casals T, Desax MC, **Gallati S**, Gomez-Lira M, Audrezet MP, Férec C, des Georges M, Claustres M, Truninger K. Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. *Hum Mutat* 2011; 32: 912-920.
133. Nicoulaz A, Rubi F, Lieder L, Wolf R, Goeggel-Simonetti B, Steinlin M, Wiest R, Bonel HM, Schaller A, **Gallati S**, Conrad B. Contiguous ~16 Mb 1p36 deletion: Dominant features of classical distal 1p36 monosomy with haplolethality. *Am J Med Genet A* 2011; 155A: 1964-1968.
134. Von Känel T, Gerber D, Wittwer CT, Hermann M, **Gallati S**. Detecting and resolving position-dependent temperature effects in real-time quantitative polymerase chain reaction. *Anal Biochem*. 2011; 419: 161-167.
135. Barben J, **Gallati S**, Fingerhut R, Schoeni MH, Baumgartner MR, Torresani T; SWISS CF SCREENING GROUP. Retrospective analysis of stored dried blood spots from children with cystic fibrosis and matched controls to assess the performance of a proposed newborn screening protocol in Switzerland. *J Cyst Fibros* 2012; 11: 332-336.
136. Lemke JR, Riesch E, Scheurenbrand T, Schubach M, Wilhelm C, Steiner I, Hansen J, Courage C, **Gallati S**, Bürki S, Strozzi S, Simonetti BG, Grunt S, Steinlin M, Alber M, Wolff M, Klopstock T, Prott EC, Lorenz R, Spaich C, Rona S, Lakshminarasimhan M, Kröll J, Dorn T, Krämer G, Synofzik M, Becker F, Weber YG, Lerche H, Böhm D, Biskup S. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. *Epilepsia* 2012; 53: 1387-1398.
137. Jackson CB, **Gallati S**, Schaller A. qPCR-based mitochondrial DNA quantification: Influence of template DNA fragmentation on accuracy. *Biochem Biophys Res Comm* 2012; 423: 441-447.
138. Nair AV, Hocher B, Verkaart S, van Zeeland F, Pfab T, Slowinski T, Chen YP, Schlingmann KP, Schaller A, **Gallati S**, Bindels RJ, Konrad M, Hoenderop JG. Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. *Proc Natl Acad Sci U S A* 2012; 109:11324-11329.
139. Goeggel Simonetti B, Rieubland C, Courage C, Strozzi S, Tschumi S, **Gallati S**, Lemke JR. Duplication of the sodium channel gene cluster on 2q24 in children with early onset epilepsy. *Epilepsia* 2012; 53: 2128-2134.
140. Gisler FM, von Kanel T, Kraemer R, Schaller A, **Gallati S**. Identification of SNPs in the cystic fibrosis interactome influencing pulmonary progression in cystic fibrosis. *Eur J Hum Genet* 2013; 21: 397-403.
141. Rueegg CS, Kuehni CE, **Gallati S**, Baumgartner M, Torresani T, Barben J; Swiss CF Screening Task Force. One-year evaluation of a neonatal screening program for cystic fibrosis in Switzerland. *Dtsch Arztebl Int* 2013; 110: 356-363.
142. von Kanel T, Stanke F, Weber M, Schaller A, Racine J, Kraemer R, Chanson M, Tümmler B, **Gallati S**. Clinical and molecular characterization of the potential CF disease modifier syntaxin 1A. *Eur J Hum Genet* 2013; 21: 1462-1466.
143. Torresani T, Fingerhut R, Rueegg CS, **Gallati S**, Kuehni CE, Baumgartner MR, Barben J; The Swiss CF Screening Group. Newborn screening for cystic fibrosis in Switzerland - Consequences after analysis of a 4 months pilot study. *J Cyst Fibros* 2013; 12: 667-674.
144. Jackson CB, Nuoffer JM, Hahn D, Prokisch H, Haberberger B, Gautschi M, Häberli A, **Gallati S**, Schaller A. Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency. *J Med Genet* 2014; 51: 170-175.
145. Stickel F, Buch S, Zoller H, Hultcrantz R, **Gallati S**, Osterreicher C, Finkenstedt A, Stadlmayr A, Aigner E, Sahinbegovic E, Sarrazin C, Schafmayer C, Braun F, Erhart W, Nothnagel M, Lerch MM, Mayerle J, Völzke H,

- Schaller A, Kratzer W, Boehm BO, Sipos B, D'Amato M, Torkvist L, Stal P, Arlt A, Franke A, Becker T, Krawczak M, Zwerina J, Berg T, Hinrichsen H, Krones E, Dejaco C, Strasser M, Datz C, Hampe J. Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. *Hum Mol Genet* 2014; Mar 3. [Epub ahead of print]
146. Jackson CB, Zbinden C, **Gallati S**, Schaller A. Heterologous expression from the human D-Loop in organello. *Mitochondrion* 2014;17: 67-75.
147. Courage C, Houge G, **Gallati S**, Schjelderup J, Rieubland C. 15q26.1 microdeletion encompassing only CHD2 and RGMA in two adults with moderate intellectual disability, epilepsy and truncal obesity. *Eur J Med Genet* 2014; 57: 520-523.
148. Jackson CB, Neuwirth C, Hahn D, Nuoffer JM, Frank S, **Gallati S**, Schaller A. Novel mitochondrial tRNA(Ile) m.4282A>G gene mutation leads to chronic progressive external ophthalmoplegia plus phenotype. *Br J Ophthalmol* 2014; 98: 1453-1459.
149. **Gallati S**. Disease-modifying genes and monogenic disorders: experience in cystic fibrosis. *Appl Clin Genet* 2014; 7: 133-146.
150. Syrbe S, Hedrich UB, Riesch E, Djémié T, Müller S, Møller RS, Maher B, Hernandez-Hernandez L, Synofzik M, Caglayan HS, Arslan M, Serratosa JM, Nothnagel M, May P, Krause R, Löffler H, Detert K, Dorn T, Vogt H, Krämer G, Schöls L, Mullis PE, Linnankivi T, Lehesjoki AE, Sterbova K, Craiu DC, Hoffman-Zacharska D, Korff CM, Weber YG, Steinlin M, **Gallati S**, Bertsche A, Bernhard MK, Merkschlager A, Kiess W; EuroEPINOMICS RES, Gonzalez M, Züchner S, Palotie A, Suls A, De Jonghe P, Helbig I, Biskup S, Wolff M, Maljevic S, Schüle R, Sisodiya SM, Weckhuysen S, Lerche H, Lemke JR. De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. *Nat Genet* 2015; 47: 393-399.